

Meniere Disease Therapeutic and Overview Pipeline Review H2

Meniere Disease Treatment Pipeline Review H2 2016

PUNE, INDIA, November 15, 2016

[/EINPresswire.com/](http://EINPresswire.com/) -- The report provides comprehensive information on the therapeutics under

development for [Meniere Disease](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the

descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/393599-meni-ere-disease-pipeline-review-h1-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Meniere Disease
- The report reviews pipeline therapeutics for Meniere Disease by companies and



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Meniere Disease therapeutics and enlists all their major and minor projects
- The report assesses Meniere Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Meniere Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Meniere Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Meniere Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Meniere Disease Overview 6

Therapeutics Development 7

Pipeline Products for Meniere Disease - Overview 7

Meniere Disease - Therapeutics under Development by Companies 8

Meniere Disease - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products	10
Early Stage Products	11
Unknown Stage Products	12
Meniere Disease - Products under Development by Companies	13
Meniere Disease - Companies Involved in Therapeutics Development	14
Orbis Biosciences, Inc.	14
Otonomy, Inc.	15
Quark Pharmaceuticals, Inc.	16
Sound Pharmaceuticals, Inc.	17
Synphora AB	18
Meniere Disease - Therapeutics Assessment	19
Assessment by Monotherapy Products	19
Assessment by Target	20
Assessment by Mechanism of Action	22
Assessment by Route of Administration	24
Assessment by Molecule Type	26
Drug Profiles	28
betamethasone valerate ER - Drug Profile	28
Product Description	28
Mechanism of Action	28
R&D Progress	28
dexamethasone acetate SR - Drug Profile	29
Product Description	29
Mechanism of Action	29
R&D Progress	29
latanoprost - Drug Profile	31
Product Description	31
Mechanism of Action	31
R&D Progress	31
OR-105 - Drug Profile	32
Product Description	32

Access Report @ <https://www.wiseguyreports.com/reports/393599-meni-ere-disease-pipeline-review-h1-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/353980141>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.